Nuvilex (PMCB) Stock Price, News & Analysis

Company Overview

Nuvilex, Inc. was a biotechnology company that developed therapies for cancer and other serious diseases. The company focused on combining cellular therapy with drug-delivery technologies intended to provide localized treatment while limiting exposure to healthy tissue.

Its principal program involved the Cell-in-a-Box technology, which uses encapsulated genetically engineered cells to convert certain chemotherapy prodrugs into active cancer-fighting compounds at or near a tumor. Nuvilex applied this approach primarily to pancreatic cancer, including a planned treatment regimen involving encapsulated cells and ifosfamide.

Nuvilex later changed its name to PharmaCyte Biotech, Inc. and continued development of the Cell-in-a-Box platform under the PharmaCyte Biotech name. Publicly available information about Nuvilex’s operations, geographic reach, and leadership is primarily historical because the company no longer operates under the Nuvilex name.

Key Stats

• Today's Range: $0.35 to $0.36
• 50-Day Range: $0.35 to $0.59
• 52-Week Range: $0.33 to $1.51
• Volume: 16,034 shs
• Average Volume: 200,292 shs
• Market Capitalization: $3.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Nuvilex Stock Analysis - MarketRank™

Nuvilex scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Nuvilex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nuvilex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvilex is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvilex is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvilex has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.40% of the float of Nuvilex has been sold short.

Short Interest Ratio / Days to Cover

Nuvilex has a short interest ratio ("days to cover") of 0.25, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuvilex has recently increased by 90.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvilex does not currently pay a dividend.

Dividend Growth

Nuvilex does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.54

News Sentiment

Nuvilex has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Nuvilex this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for PMCB on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuvilex insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.98% of the stock of Nuvilex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

34.24% of the stock of Nuvilex is held by institutions.

Company Calendar

• Last Earnings: 9/14/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 12/16/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PMCB
• CIK: 1157075
• Web: pharmacyte.com
• Phone: 917-595-2850
• Fax: 917-595-2851
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -12.99%
• Return on Assets: -8.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 40.28
• Quick Ratio: 40.28

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 10,740,000
• Free Float: 9,557,000
• Market Cap: $3.78 million
• Optionable: Optionable
• Beta: 0.68